HERZLIYA, Israel, March 17, 2026
Regentis Biomaterials Ltd. has announced a breakthrough solvent-free manufacturing process for its lead regenerative medicine product, GelrinC®, achieving a 400% increase in production yield per batch, a major advancement ahead of its planned commercial launch in Europe later this year. The innovation eliminates the need for organic solvents, which are typically flammable, toxic, and resource-intensive, marking a significant step forward in safe, scalable, and cost-efficient medical product manufacturing.
Innovative Manufacturing Enhances Yield and Safety
The newly developed process represents a major technological advancement in biomaterials manufacturing, as it removes reliance on organic solvents that traditionally occupy a large portion of production volume and introduce safety risks. By implementing a solvent-free approach, Regentis has not only improved manufacturing efficiency but also enhanced environmental and operational safety standards, aligning with increasing global emphasis on sustainable production practices.
The most notable outcome is the more than fourfold increase in production yield, which directly translates into improved scalability and reduced cost per unit, critical factors for successful commercialization. This advancement is particularly relevant in regulated environments where Good Manufacturing Practice (GMP) compliance, process consistency, and safety are essential. The ability to produce higher volumes with fewer hazards positions Regentis strongly in the competitive regenerative medicine market.
GelrinC Positioned for Commercial Launch and Market Expansion
Advertisement
GelrinC® is an off-the-shelf, cell-free hydrogel implant designed for the treatment of focal articular knee cartilage injuries, offering a simple, single-procedure solution that supports tissue regeneration and long-term functional improvement. The product already holds CE Mark approval in the European Union, enabling its upcoming commercial launch, while a pivotal U.S. FDA clinical study is currently underway with over 50% enrollment completed.
This dual regulatory pathway highlights the product’s global commercialization potential, with Europe serving as the initial market entry point and the United States representing a significant future opportunity. The enhanced manufacturing process is expected to support large-scale production demands and improve gross margins, making the product more accessible and economically viable for healthcare providers and patients.
Importantly, GelrinC addresses a substantial unmet medical need, as there are currently no widely available off-the-shelf treatments for cartilage repair, despite an estimated 470,000 cases annually in the U.S. alone. This positions the product as a potential game-changer in orthopedic regenerative medicine, with strong clinical and commercial relevance.
Global Patent Strategy Strengthens Competitive Position
To protect its innovation, Regentis has implemented a robust intellectual property strategy, securing patents for the solvent-free manufacturing process in multiple regions, including India, China, and Israel, while additional patents are currently pending in the United States. This global patent coverage not only safeguards the company’s technological advancements but also enhances its long-term competitive advantage in the biomaterials and regenerative medicine space.
The integration of advanced manufacturing innovation with strong IP protection is critical for maintaining leadership in a rapidly evolving industry. As the company moves closer to commercialization, these patents will play a key role in ensuring exclusivity and supporting strategic partnerships or licensing opportunities.
The development of a solvent-free manufacturing process that increases GelrinC production yield by 400% represents a significant milestone for Regentis Biomaterials, combining technological innovation, improved safety, and enhanced scalability. As the company prepares for its European launch and advances its U.S. clinical program, this breakthrough strengthens its position in the regenerative medicine market. With a focus on efficient manufacturing, regulatory compliance, and unmet clinical needs, Regentis is well-positioned to deliver a next-generation solution for cartilage repair and tissue regeneration, making this development highly relevant for stakeholders across the medical and regulatory landscape.
Source: regentis biomaterials press release
